Clinical Trials, Phase, Cell, Transplantation, Dose, Malignancies, Allogeneic, Hematologic, Donor, Treatment, Fludarabine, Marrow, Autologous, Blood, HLA, Lymphoma, Leukemia, Hematopoietic, Protocol, Alemtuzumab, Myeloablative, Tumor, Campath, Immunosuppression, Peripheral, Randomized, Nonmyeloablative, Etoposide, Posaconazole, Multicenter, Rasburicase : Rocky Mountain Blood and Marrow Transplant (RMBMT)

News | Events | Glossary | Print this page

Search this site

	Patients & Caregivers
	Clinical Trials
	Program Statistics
	Referrals
	Continuing Care
	Diseases
	Patient Stories

	Our Physicians
	Our Team
	P/SL Medical Center
	Rocky Mountain Cancer Centers
	Becoming a Donor
	Donations
	Volunteering
	Resources
	Psychology Fellowship Training
	Contact Us


	Clinical Trials We are committed to developing innovative therapies for blood cancers, bone marrow diseases and disorders. Our cutting edge research insures our patients are receiving the most progressive therapies available. Acute Lymphocytic Leukemia (ALL) Acute Myeloid Leukemia (AML) Amyloidosis Aplastic Anemia Chronic Lymphocytic Leukemia (CLL) Chronic Myeloid Leukemia (CML) Hodgkin Lymphoma Multiple Myeloma Myelodysplastic Syndrome (MDS) Non-Hodgkin Lymphoma (NHL) Testicular Cancer Acute Lymphocytic Leukemia (ALL) Standard Treatments Total Body Irradiation with Cyclphosphamide Or Etoposide As Preparative Therapy For Autologous And Allogeneic Stem Cell Transplantation: Standard Care Treatment Protocol Clinical Trials 1581 - Allogeneic Nonmyeloablative Hematopoietic Stem Cell Transplant for Patients with STI-571 Responsive Ph+ Acute Leukemia - Multi-Center Trial 1938 - A Randomized Phase II Study to Determine the Most Promising Postgrafting Immunosuppression for Prevention of Acute GVHD after Unrelated Donor G-CSF mobilized Peripheral Blood Mononuclear Cell (G-PBMC) Transplantation using Nonmyeloablative Conditioning for Patients with Hematologic Malignancies A Multi-Center Trial Campath (Alemtuzumab) Dose Escalation, Low-Dose TBI and Fludarabine Followed by HLA Class II Mismatched Donor Stem Cell Transplantation For Patients With Hematologic Malignancies - A Multicenter Trial Tacrolimus and Mycophenolate Mofetil as Post-Grafting Immunosuppression after Conditioning with Fludarabine and Low-Dose Total Body Irradiation for Recipients of HLA Matched Family Donor Hematopoietic Cell Transplants Treatment Of Hematologic Malignancies With High-Dose Chemo-Radiotherapy Followed By Single-Unit Or Double-Unit Cord Blood Transplantation: A Phase II Study Acute Myeloid Leukemia (AML) Standard Treatments Fludarabine and Once-Daily Intravenous Busulfan Conditioning Prior to Allogeneic Hematopoietic Stem Cell Transplantation Total Body Irradiation with Cyclphosphamide Or Etoposide As Preparative Therapy For Autologous And Allogeneic Stem Cell Transplantation: Standard Care Treatment Protocol Clinical Trials 1938 - A Randomized Phase II Study to Determine the Most Promising Postgrafting Immunosuppression for Prevention of Acute GVHD after Unrelated Donor G-CSF mobilized Peripheral Blood Mononuclear Cell (G-PBMC) Transplantation using Nonmyeloablative Conditioning for Patients with Hematologic Malignancies A Multi-Center Trial 1992 - A Multi-center Phase III Study Comparing Myeloablative to Nonmyeloablative Transplant Conditioning in Patients with Myelodysplastic Syndrome or Acute Myelogenous Leukemia A Phase 2 Open Label Mulitcenter Clinical Study of the Safety and Efficacy of SNS-595 Injection in Patients ≥ 60 Years of Age with Previously Untreated Acute Myeloid Leukemia Campath (Alemtuzumab) Dose Escalation, Low-Dose TBI and Fludarabine Followed by HLA Class II Mismatched Donor Stem Cell Transplantation For Patients With Hematologic Malignancies - A Multicenter Trial Phase 3 Open-Label Randomized Study of Amonafide L-Malate in Combination with Cytarabine Compared to Daunorubicin in Combination with Cytarabine in Patients with Secondary Acute Myeloid Leukemia (AML) Tacrolimus and Mycophenolate Mofetil as Post-Grafting Immunosuppression after Conditioning with Fludarabine and Low-Dose Total Body Irradiation for Recipients of HLA Matched Family Donor Hematopoietic Cell Transplants Tacrolimus And Mycophenolate Mofetil As Post-Grafting Immunosuppression After Conditioning With Fludarabine and Low-Dose Total Body Irradiation For Recipients of HLA-Matched Family or Unrelated Donor Hematopoietic Cell Transplants. Treatment Of Hematologic Malignancies With High-Dose Chemo-Radiotherapy Followed By Single-Unit Or Double-Unit Cord Blood Transplantation: A Phase II Study Amyloidosis Standard Treatments A Multicenter Phase II Trial of Bortezomib (Velcade), Melphalan, and Dexamethasone (V-MD) in Patients with Symptomatic AL-Amyloidosis or Light Chain Deposition Disease A Treatment Guideline for High-Dose Melphalan with Autologous Hematopoietic Stem Cell Reconstitution for Primary Systemic Amyloidosis Aplastic Anemia Standard Treatments Cyclophosphamide and Antithymocyte Globulin, With or Without Total Body Irradiation, Followed By Allogeneic Hematopoietic stem Cell Transplantation For Severe Aplastic Anemia Chronic Lymphocytic Leukemia (CLL) Standard Treatments Total Body Irradiation with Cyclphosphamide Or Etoposide As Preparative Therapy For Autologous And Allogeneic Stem Cell Transplantation: Standard Care Treatment Protocol Clinical Trials 1938 - A Randomized Phase II Study to Determine the Most Promising Postgrafting Immunosuppression for Prevention of Acute GVHD after Unrelated Donor G-CSF mobilized Peripheral Blood Mononuclear Cell (G-PBMC) Transplantation using Nonmyeloablative Conditioning for Patients with Hematologic Malignancies A Multi-Center Trial Campath (Alemtuzumab) Dose Escalation, Low-Dose TBI and Fludarabine Followed by HLA Class II Mismatched Donor Stem Cell Transplantation For Patients With Hematologic Malignancies - A Multicenter Trial Tacrolimus and Mycophenolate Mofetil as Post-Grafting Immunosuppression after Conditioning with Fludarabine and Low-Dose Total Body Irradiation for Recipients of HLA Matched Family Donor Hematopoietic Cell Transplants Chronic Myeloid Leukemia (CML) Standard Treatments Total Body Irradiation with Cyclphosphamide Or Etoposide As Preparative Therapy For Autologous And Allogeneic Stem Cell Transplantation: Standard Care Treatment Protocol Clinical Trials 1581 - Allogeneic Nonmyeloablative Hematopoietic Stem Cell Transplant for Patients with STI-571 Responsive Ph+ Acute Leukemia - Multi-Center Trial 1938 - A Randomized Phase II Study to Determine the Most Promising Postgrafting Immunosuppression for Prevention of Acute GVHD after Unrelated Donor G-CSF mobilized Peripheral Blood Mononuclear Cell (G-PBMC) Transplantation using Nonmyeloablative Conditioning for Patients with Hematologic Malignancies A Multi-Center Trial Campath (Alemtuzumab) Dose Escalation, Low-Dose TBI and Fludarabine Followed by HLA Class II Mismatched Donor Stem Cell Transplantation For Patients With Hematologic Malignancies - A Multicenter Trial Tacrolimus and Mycophenolate Mofetil as Post-Grafting Immunosuppression after Conditioning with Fludarabine and Low-Dose Total Body Irradiation for Recipients of HLA Matched Family Donor Hematopoietic Cell Transplants Treatment Of Hematologic Malignancies With High-Dose Chemo-Radiotherapy Followed By Single-Unit Or Double-Unit Cord Blood Transplantation: A Phase II Study Hodgkin Lymphoma Standard Treatments Total Body Irradiation with Cyclphosphamide Or Etoposide As Preparative Therapy For Autologous And Allogeneic Stem Cell Transplantation: Standard Care Treatment Protocol Treatment of Non-Hodgkin Lymphoma with High-Dose Carmustine, Etoposide, Cytarabine, and Cyclophosphamide (BEAC) or Melphalan (BEAM) Followed by Autologous Peripheral Blood Progenitor Cells Standard Care Treatment Protocol Clinical Trials 1938 - A Randomized Phase II Study to Determine the Most Promising Postgrafting Immunosuppression for Prevention of Acute GVHD after Unrelated Donor G-CSF mobilized Peripheral Blood Mononuclear Cell (G-PBMC) Transplantation using Nonmyeloablative Conditioning for Patients with Hematologic Malignancies A Multi-Center Trial Campath (Alemtuzumab) Dose Escalation, Low-Dose TBI and Fludarabine Followed by HLA Class II Mismatched Donor Stem Cell Transplantation For Patients With Hematologic Malignancies - A Multicenter Trial Tacrolimus and Mycophenolate Mofetil as Post-Grafting Immunosuppression after Conditioning with Fludarabine and Low-Dose Total Body Irradiation for Recipients of HLA Matched Family Donor Hematopoietic Cell Transplants Treatment of Relapsed or Primary Refractory Hodgkin Lymphoma with High-Dose CBV Followed by Autologous Peripheral Blood Progenitor Cell Rescue Multiple Myeloma Standard Treatments High Dose Melphalan and Autologous Peripheral Blood Stem Cell Transplant As Rescue Therapy for Multiple Myeloma Total Body Irradiation with Cyclphosphamide Or Etoposide As Preparative Therapy For Autologous And Allogeneic Stem Cell Transplantation: Standard Care Treatment Protocol Clinical Trials 1938 - A Randomized Phase II Study to Determine the Most Promising Postgrafting Immunosuppression for Prevention of Acute GVHD after Unrelated Donor G-CSF mobilized Peripheral Blood Mononuclear Cell (G-PBMC) Transplantation using Nonmyeloablative Conditioning for Patients with Hematologic Malignancies A Multi-Center Trial Campath (Alemtuzumab) Dose Escalation, Low-Dose TBI and Fludarabine Followed by HLA Class II Mismatched Donor Stem Cell Transplantation For Patients With Hematologic Malignancies - A Multicenter Trial Tacrolimus and Mycophenolate Mofetil as Post-Grafting Immunosuppression after Conditioning with Fludarabine and Low-Dose Total Body Irradiation for Recipients of HLA Matched Family Donor Hematopoietic Cell Transplants Non-Hodgkin Lymphoma (NHL) Standard Treatments Total Body Irradiation with Cyclphosphamide Or Etoposide As Preparative Therapy For Autologous And Allogeneic Stem Cell Transplantation: Standard Care Treatment Protocol Treatment of Non-Hodgkin Lymphoma with High-Dose Carmustine, Etoposide, Cytarabine, and Cyclophosphamide (BEAC) or Melphalan (BEAM) Followed by Autologous Peripheral Blood Progenitor Cells Standard Care Treatment Protocol Clinical Trials 1938 - A Randomized Phase II Study to Determine the Most Promising Postgrafting Immunosuppression for Prevention of Acute GVHD after Unrelated Donor G-CSF mobilized Peripheral Blood Mononuclear Cell (G-PBMC) Transplantation using Nonmyeloablative Conditioning for Patients with Hematologic Malignancies A Multi-Center Trial Campath (Alemtuzumab) Dose Escalation, Low-Dose TBI and Fludarabine Followed by HLA Class II Mismatched Donor Stem Cell Transplantation For Patients With Hematologic Malignancies - A Multicenter Trial Tacrolimus and Mycophenolate Mofetil as Post-Grafting Immunosuppression after Conditioning with Fludarabine and Low-Dose Total Body Irradiation for Recipients of HLA Matched Family Donor Hematopoietic Cell Transplants Treatment Of Hematologic Malignancies With High-Dose Chemo-Radiotherapy Followed By Single-Unit Or Double-Unit Cord Blood Transplantation: A Phase II Study Treatment of Non-Hodgkin Lymphoma with High-Dose Carmustine, Etoposide, Cytarabine, and Melphalan (BEAM) Followed by Allogeneic Marrow or Peripheral Blood Stem Cell Transplantation